Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 1,488 Cr.
- Current Price ₹ 285
- High / Low ₹ 354 / 231
- Stock P/E 44.7
- Book Value ₹ 44.2
- Dividend Yield 0.00 %
- ROCE 17.8 %
- ROE 16.5 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 6.44 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 9.86% over past five years.
- Company has a low return on equity of 12.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 158 | 140 | 223 | 190 | 219 | 252 | 294 | |
| 123 | 115 | 175 | 143 | 146 | 170 | 204 | |
| Operating Profit | 34 | 25 | 48 | 47 | 73 | 82 | 90 |
| OPM % | 22% | 18% | 22% | 25% | 33% | 33% | 31% |
| 2 | -1 | 2 | 1 | 1 | 4 | 3 | |
| Interest | 2 | 2 | 2 | 10 | 10 | 9 | 11 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 39 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 44 |
| Tax % | 28% | -1% | 28% | 10% | 26% | 25% | |
| 15 | 6 | 24 | 6 | 23 | 31 | 32 | |
| EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 | 6.11 | 6.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 4% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 10% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 13% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 220 |
| 13 | 18 | 21 | 99 | 92 | 89 | 118 | |
| 42 | 28 | 32 | 28 | 30 | 33 | 32 | |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 380 |
| 128 | 119 | 119 | 195 | 212 | 223 | 277 | |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 2 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 |
| 39 | 46 | 80 | 84 | 87 | 99 | 101 | |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 380 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31 | 24 | 42 | 44 | 60 | 63 | |
| -20 | -28 | -44 | -21 | -35 | -40 | |
| -10 | 3 | 1 | -24 | -25 | -24 | |
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 12 | 9 | 15 | 20 |
| Inventory Days | 93 | 62 | 38 | 82 | 89 | 100 |
| Days Payable | 227 | 177 | 84 | 187 | 193 | 169 |
| Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 | -49 |
| Working Capital Days | -35 | -19 | -15 | -49 | -37 | -23 |
| ROCE % | 8% | 23% | 9% | 17% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
12 Feb - Transcript of the Earnings Call held on Friday, 06 February, 2026 at 02:30 pm.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
6 Feb - Suraksha Diagnostic posts Q3 FY26 earnings-call audio (06 Feb 2026) for quarter and nine months ending 31 Dec 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Feb - Newspaper publication of unaudited (standalone and consolidated) financial results for quarter and nine months ended 31 December 2025
-
Announcement under Regulation 30 (LODR)-Investor Presentation
5 Feb - Investor Presentation on the unaudited (standalone and consolidated) financial results of the Company for the quarter and nine months ended 31 December 2025
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 Feb - Q3 FY26: Total income ₹783.09m (+30.3%), EBITDA ₹237.82m, PAT ₹72.41m; added 12 centres; launched genomics vertical.
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Dec 2024TranscriptAI SummaryPPT
Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 1,000+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.